Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Seres Therapeutics Q3 2026 Results: Net Loss of $16.3M

Seres Therapeutics is a clinical-stage company that has identified conditions raising substantial doubt about its ability to continue as a going concern. The company reported 10,195,031 shares of common stock outstanding as of November 2, 2026, and is seeking additional funding or strategic partnerships to advance its SER-155 clinical programs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.60.4
Net income-16.38.2
EPS (diluted, $ a share)$-1.63$0.94

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+68.9%
Source

10-Q filed with the SEC, NASDAQ: MCRB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Seres Therapeutics, Inc.: key numbers

Share price
$1.41Close, Nov 16
Market cap
$14.4M
Shares outstanding
10.2MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Seres Therapeutics, Inc.

All →
7:05 AM ET 8-K
Financial Results

Seres Therapeutics Financial Results

Seres Therapeutics reported Q3 2026 financial results and announced plans to advance SER-155 into a study for the prevention of immune checkpoint inhibitor-related enterocolitis (irEC). The company expects to submit the study design to the FDA in Q1 2027 following positive investigator-sponsored trial results showing an 80% clinical response rate.

Term
Q3 2026

“The irEC IST provided promising evidence that orally administered SER-155 improved epithelial barrier integrity and reduced gastrointestinal inflammation without systemic immunosuppression and was well-tolerated in patients with ICI-induced enterocolitis.”

Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres

“We believe SER-155 may enable ICI patients, of whom there are currently estimated to be approximately 300,000 in the U.S. alone, to remain on their therapy by reducing the occurrence of irEC, which often requires the halting of life-saving cancer treatment.”

Richard Kender, Executive Chairman and Interim Chief Executive Officer of Seres
4:30 PM ET 8-K
Leadership Change

Seres Therapeutics Leadership Change

Marella Thorell, Executive Vice President and Chief Financial Officer of Seres Therapeutics, Inc., resigned from her positions effective November 15, 2026. She is expected to provide advisory services to the company following her departure to support an orderly transition.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.